COMP <GO>
LMRI vs CSTL // EV/EBITDA & P/E VALUATION
Lumexa Imaging Holdings Inc. (NASDAQ) VS. Castle Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: LMRI 0
— CSTL 2
■ METRIC PARITY
LAST: $11.73 (+0.95%) • MKT CAP: $1.13B
valuation
—
LAST: $38.51 (+4.99%) • MKT CAP: $1.18B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LMRI VS. CSTL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LMRI | CSTL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 79.40% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -9.30% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 2.41% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -12.40% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -7.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 3.70% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 6.97 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 6/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.4 | 60.9 | -3.50 | CSTL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.13B | $1.18B | -$49.5M | CSTL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LMRI REV | CSTL REV | LMRI GROSS % | CSTL GROSS % | LMRI FCF | CSTL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $344.2M | — | 79.4% | — | $28.3M |
| FY 2024 | — | $332.1M | — | 81.9% | — | $36.5M |
| FY 2023 | — | $219.8M | — | — | — | -$5.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LMRI // BETA —
CSTL // BETA —